Overview

Study Comparing Simulect Plus Standard Immunosuppression to Standard Immunosuppression Alone for the Prevention of Acute Rejection and Bronchiolitis Obliterans in Lung Transplant

Status:
Completed

Trial end date:
2007-10-01

Target enrollment:

Participant gender:

Summary

The study will evaluate the efficacy and safety of basiliximab Vs placebo as induction therapy combined with standard triple immunosuppression therapy, in the prevention of acute rejection episodes and prevention of Bronchiolitis Obliterans Syndrome.

Phase:

Phase 3

Details

Lead Sponsor:

University Health Network, Toronto

Collaborator:

Novartis

Treatments:

Basiliximab